Neuroendocrine tumours: markers, grading and functional imaging
- Diagnostic approach
Hormone-making tumours can hide for years in the gut, pancreas or lung. What they make, how fast they grow and where they are guides every decision.
What it is
Neuroendocrine tumours (NETs) arise from the hormone-making cells scattered through the gut, pancreas and lung, and less often the thymus and other sites. The small intestine, rectum, appendix, stomach, pancreas and bronchi are the usual primaries. Functioning NETs secrete a hormone that causes a syndrome (serotonin, insulin, gastrin, glucagon, VIP, somatostatin, ACTH); most pancreatic and many gut NETs are non-functioning and present with mass effect, liver metastases or as an incidental finding. Pathology confirms neuroendocrine nature (synaptophysin, chromogranin A staining) and separates well-differentiated NETs, graded G1 to G3 by Ki-67 index and mitotic count (WHO), from poorly differentiated neuroendocrine carcinomas (small-cell or large-cell type), which behave like aggressive cancers.
What to know
- Functional diagnosis pairs the hormone with the state it should be suppressed in: insulin with low glucose, gastrin with gastric pH, 5-HIAA for serotonin.
- Chromogranin A is a general NET marker for follow-up, not a screening test: proton-pump inhibitors, atrophic gastritis, kidney failure and heart failure raise it falsely.
- WHO grading of well-differentiated gastroenteropancreatic NETs: G1 Ki-67 below 3%, G2 3–20%, G3 above 20%; poorly differentiated neuroendocrine carcinoma is a separate, more aggressive entity.
- Somatostatin-receptor PET/CT (gallium-68 or copper-64 DOTATATE) is the most sensitive staging scan for well-differentiated NETs and selects patients for somatostatin analogues and peptide receptor radionuclide therapy.
- Poorly differentiated carcinomas and many insulinomas carry few somatostatin receptors: FDG PET suits the carcinomas; endoscopic ultrasound or GLP-1 receptor imaging help find insulinomas.
- About a quarter of gastrinomas, and many pancreatic NETs in young patients, are part of MEN1.
- Small-intestinal NETs are often found late, with liver metastases, mesenteric fibrosis or bowel obstruction.
Step-by-step approach
- Suspect a NET from a hormone syndrome, an unexplained liver or pancreatic mass, or an incidental finding at endoscopy or imaging.
- If there is a syndrome, prove the hormone excess first: measure the matching hormone in the state in which it should be suppressed.
- Confirm on tissue: synaptophysin and chromogranin A staining, differentiation, Ki-67 index and mitotic count.
- Stage with multiphase CT or liver MRI and somatostatin-receptor PET/CT; add FDG PET for high-grade tumours.
- Look for MEN1 or another inherited syndrome when the patient is young, tumours are multiple or calcium is high.
- Control the hormone before procedures: a somatostatin analogue for most; diazoxide and frequent meals for insulinoma.
- Plan in a NET team: surgery for localised disease; somatostatin analogues, radionuclide therapy, targeted drugs or chemotherapy when advanced.
The functional pancreatic and duodenal NETs side by side
| Tumour | Hormone | Telltale picture | Key test | Site and behaviour |
|---|---|---|---|---|
| Insulinoma | Insulin | Hypoglycaemia when fasting or exercising, relieved by eating (Whipple triad); weight gain | Supervised fast: low glucose with inappropriately high insulin, C-peptide and proinsulin | Anywhere in the pancreas, usually single and small; about 90% benign |
| Gastrinoma (Zollinger–Ellison) | Gastrin | Multiple or refractory ulcers, ulcers beyond the duodenal bulb, diarrhoea | High fasting gastrin with acid gastric pH; secretin test when unclear | Duodenum more than pancreatic head (gastrinoma triangle); mostly malignant |
| Glucagonoma | Glucagon | Necrolytic migratory erythema, diabetes, weight loss, venous thrombosis | High glucagon | Body and tail; mostly malignant |
| VIPoma | VIP | Large-volume watery diarrhoea that continues while fasting, low potassium, low gastric acid | High VIP during the diarrhoea | Body and tail; mostly malignant |
| Somatostatinoma | Somatostatin | Diabetes, gallstones and fatty stools: everything switched off | High somatostatin; often found as a mass | Pancreatic head or duodenum (duodenal ones linked to NF1); mostly malignant |
| Non-functioning NET | None that causes symptoms | Mass effect, jaundice, liver metastases or an incidental finding | Tissue diagnosis and staging | The commonest pancreatic NET; behaviour set by size and grade |
Keys to the differential
- Diarrhoea has many NET causes: serotonin, VIP (fasting does not stop it), gastrin (acid inactivates pancreatic lipase), somatostatin (fat malabsorption) and somatostatin analogue treatment itself.
- A NET found at colonoscopy or appendicectomy is sized and graded before deciding on more surgery; small rectal and appendiceal NETs are usually cured by removal.
- Somatostatin analogues improve most hormone syndromes but can worsen hypoglycaemia in some insulinomas, because they also suppress glucagon and growth hormone.
- Poorly differentiated neuroendocrine carcinoma behaves like small-cell lung cancer and is treated with chemotherapy, not as a slow NET.
Next step / Initial management
- The hormone that fits the syndrome (insulin with glucose, gastrin with gastric pH, glucagon, VIP, urine or plasma 5-HIAA), with chromogranin A as a follow-up marker.
- Biopsy for differentiation and Ki-67; stage with multiphase CT or liver MRI and somatostatin-receptor PET/CT.
- Control symptoms while staging: somatostatin analogue; proton-pump inhibitor for gastrinoma; diazoxide and frequent meals for insulinoma.
- Calcium, PTH and prolactin when MEN1 is possible, and genetic testing if they are abnormal or the patient is young.
- Refer every suspected or confirmed NET to a multidisciplinary neuroendocrine tumour team (endocrinology, surgery, oncology, nuclear medicine).
Common traps
- A high chromogranin A proves a NET: proton-pump inhibitors, atrophic gastritis and kidney failure raise it, so it is a follow-up marker, not a diagnostic test.
- A high gastrin means a gastrinoma: the commonest causes are acid-suppressing drugs and atrophic gastritis, where gastrin is high because acid is low; gastrinoma is high gastrin with an acid stomach.
- A grade 3 NET is the same as a neuroendocrine carcinoma: G3 NETs are well differentiated and often slower, while poorly differentiated carcinomas need platinum-based chemotherapy.
- A negative somatostatin-receptor scan rules out a NET: many insulinomas and high-grade carcinomas lack the receptor, so they need endoscopic ultrasound, GLP-1 receptor imaging or FDG PET.
- Every pancreatic NET makes a hormone: most are non-functioning and present with mass effect or liver metastases, so a normal hormone panel does not exclude one.
Test yourself
Think of the answer, then tap the question to see it.
A 50-year-old has large-volume watery diarrhoea that persists during a fast, low potassium and a mass in the pancreatic tail. Which hormone should be measured?
Vasoactive intestinal peptide (VIP): a VIPoma causes secretory diarrhoea that continues while fasting, with low potassium and low gastric acid.
A woman has recurrent jejunal ulcers and diarrhoea; fasting gastrin is high with a gastric pH of 1.5. What is the diagnosis, and what else should be checked?
Gastrinoma (Zollinger–Ellison syndrome); check calcium, PTH and prolactin, because about a quarter of gastrinomas are part of MEN1.
A liver biopsy shows a well-differentiated NET with a Ki-67 index of 8%. What grade is it, and which scan shows where else it is?
Grade 2 (Ki-67 3–20%); somatostatin-receptor PET/CT stages it and shows whether receptor-targeted treatment could work.
Why can octreotide worsen hypoglycaemia in a patient with an insulinoma?
It suppresses glucagon and growth hormone, which defend against low glucose, while many insulinomas have too few somatostatin receptors for insulin itself to fall.
Elsewhere in DurgiPedia
- Pancreatic neuroendocrine tumours
- Gastrointestinal neuroendocrine (carcinoid) tumours
- Pulmonary neuroendocrine tumours
- Multiple endocrine neoplasia (MEN) syndromes
- Islets of Langerhans: α, β, δ cells
Connections
In Pharmacology2
Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.
Sources: Pancreatic Neuroendocrine Tumors (StatPearls (NCBI Bookshelf), 2025); Gastrointestinal Neuroendocrine Tumors (StatPearls (NCBI Bookshelf), 2025); Insulinoma (StatPearls (NCBI Bookshelf), 2025); Gastrinoma (StatPearls (NCBI Bookshelf), 2025); VIPoma (StatPearls (NCBI Bookshelf), 2025); Glucagonoma (StatPearls (NCBI Bookshelf), 2025); Somatostatinoma (StatPearls (NCBI Bookshelf), 2025).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
